These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 26459251)

  • 1. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
    Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
    Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
    Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
    Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
    Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
    Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
    Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
    Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.
    Huang J; Zhou Y; Zhang H; Qu T; Mao Y; Zhu H; Quan L; Xing P; Wang J; He J; Xu N; Sun Y
    Med Oncol; 2013 Mar; 30(1):343. PubMed ID: 23263828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma.
    Zhang W; Zhu H; Liu X; Wang Q; Zhang X; He J; Sun K; Liu X; Zhou Z; Xu N; Xiao Z
    Ann Thorac Surg; 2014 Aug; 98(2):513-9. PubMed ID: 24881860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
    Chen Y; Wu X; Bu S; He C; Wang W; Liu J; Guo W; Tan B; Wang Y; Wang J
    Cancer Sci; 2012 Nov; 103(11):1979-84. PubMed ID: 22845557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
    Kim HS; Kim SM; Kim H; Pyo KH; Sun JM; Ahn MJ; Park K; Keam B; Kwon NJ; Yun HJ; Kim HG; Chung IJ; Lee JS; Lee KH; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Kim HR; Moon YW; Lee YC; Kim JH; Paik S; Cho BC
    Oncotarget; 2015 Dec; 6(42):44971-84. PubMed ID: 26462025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
    Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
    J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.
    Wang CY; Deng JY; Cai XW; Fu XL; Li Y; Zhou XY; Wu XH; Hu XC; Fan M; Xiang JQ; Zhang YW; Chen HQ; Perez R; Jiang GL; Zhao KL
    Oncotarget; 2015 Jul; 6(21):18674-82. PubMed ID: 26124180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
    Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
    Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
    Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
    Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma.
    Si X; Wu S; Wang H; Zhang X; Wang M; Zeng X; Zhang L
    Thorac Cancer; 2018 Aug; 9(8):1056-1061. PubMed ID: 29920955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
    Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
    Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
    Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
    Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
    Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
    J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
    Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
    BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
    Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
    Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma.
    Xu Y; Peng Z; Li Z; Lu M; Gao J; Li Y; Li Y; Shen L
    BMC Cancer; 2015 Jan; 15():6. PubMed ID: 25588551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients.
    Yu W; Yang X; Chu L; Zhao K; Chen H; Xiang J; Zhang Y; Li H; Zhao W; Sun M; Wei Q; Fu X; Xie C; Zhu Z
    Pathol Res Pract; 2018 Jul; 214(7):1017-1023. PubMed ID: 29729836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.